Search

Your search keyword '"Boschetti, C."' showing total 278 results
Start Over Author "Boschetti, C."
278 results on '"Boschetti, C."'

64. The PLAT Study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. PLAT Study Group. Progetto Lombardo Atero-Trombosi (PLAT) Study Group.

Author

Cortellaro, M, primary, Boschetti, C, additional, Cofrancesco, E, additional, Zanussi, C, additional, Catalano, M, additional, de Gaetano, G, additional, Gabrielli, L, additional, Lombardi, B, additional, Specchia, G, additional, and Tavazzi, L, additional

Published
1992
Full Text
View/download PDF

80. Possible Mechanisms of Fibrin Deposition in the Hypereosinophilic Syndrome

Author

Gambacorti Passerini, C., Cortellaro, M., Cofrancesco, E., Boschetti, C., Pogliani, E., Alessio, G., Semeraro, N., Mussoni, L., and Donati, M.B.

Abstract

Patients with the hypereosinophilic syndrome (HES) are at increased risk of thrombosis and have signs of fibrin deposition in the myocardial cavity; the pathogenesis of these complications is still unknown. We have studied a 51-year-old man affected by HES with heart, lung, skin, and gastrointestinal involvement. Routine laboratory parameters of the hemostatic system were normal with the exception of blood fibrinolytic activity. The latter was evaluated by both diluted blood clot lysis time and euglobulin lytic activity on fibrin plates before and after 10 min venous occlusion. The fibrinolytic activity measured on four occasions during a 3-month period, was impaired both in basal conditions and following venous occlusion. Platelet studies on two different occasions before and during therapy showed spontaneous platelet aggregation, lowered threshold concentrations of various aggregating agents, reduced platelet regeneration time and increased plasma β-thromboglobulin concentration. The patient’s polymorphonuclear cells (more than 75% eosinophils) were devoid of any procoagulant activity (PCA). Instead, patient’s mononuclear cells studied before therapy generated significantly higher PCA on stimulation by endotoxin than cells from control subjects. The procoagulant response to endotoxin decreased markedly during therapy. The observed abnormalities could, at least partially, contribute to fibrin deposition in HES.

Published
1989
Full Text
View/download PDF

84. Current standard of care in patients affected by coronary heart disease in Italy: The MC'95 study

Author

Magnani, B., Dal Palù, C., Zanchetti, A., Paciaroni, E., Rafaeli, S., Rizzon, P., Del Laura, D., Bracchetti, D., Rubboli, A., Leonardi, G., Visioli, O., Assanelli, D., Cherchi, A., Lai, C., Fusco, C., Sanna, A., Marras, L., Crabu, E., Lazzaroli, A., Chieff, C., Di Stasio, M., Giuffrida, G., Passaniti, A., Calvi, V., Pretolani, E., Pretolani, M., Barsotti, A., Gallina, S., Finis, A., Gaeta, M., Padula, M., Plastina, F., Battista, F., Gensini, G. F., Del Pace, S., Comeglio, M., Caponnetto, S., Maragliano, P., Delfino, L., Santucci, A., Gentile, M., Giulani, E., Bellini, C., Bossi, M., Alessandro, B., Arrigo, E., Luzza, F., Frisina, N., Piccolo, E., Ragazzo, M., Fiorentini, C., Beltrami, A., Panna, S., Lanzafame, A. S., Libretti, A., Colombo, F., Polese, A., Benevento, F., Lavezzaro, G., Spinnler, M. T., Cobelli, F., Parziale, P., Chiariello, M., Perrone Filardi, P., Betocchi, S., Divitiis, O., Di Somma, S., Cudemo, G., Carotenuto, A., Sensale, P., Trevi, G. P., Magnani, A., Novo, S., Raineri, A., Marcello Traina, Leone, S., Borghetti, A., Cavatorta, A., Arisi, S., Adornini, G., Corea, L., Mariotti, M., Mariani, M., Biadi, O., Campa, P. P., Mastroianni, M. A., Plaustro, G., Prati, P., Boschetti, C., Pulcini, M., Santini, M., Magris, B., Strano, A., Sanguigni, V., Bru-Sca, A., Caruzzo, C., Milone, F., and Garbo, R.

91. Long-term results in non randomized patients with acute myelogenous leukemia: A single institution experience

Author

Gl, Deliliers, Annaloro C, Oriani A, Della Volpe A, Boschetti C, AGOSTINO CORTELEZZI, and At, Maiolo

Subjects
Adult, Male, Adolescent, Leukemia, Myeloid, Acute Disease, Antineoplastic Combined Chemotherapy Protocols, Remission Induction, Cytarabine, Humans, Female, Middle Aged, Idarubicin, Bone Marrow Transplantation
Abstract

Sixty-three non randomized adults with acute myelogenous leukemia were treated with an idarubicin-based protocol. The patients achieving complete remission received autologous bone marrow transplantation or (if50 years or refusing autologous bone marrow transplantation) high-dose Ara-C, as late intensification. Fifty-two patients (82.5%) achieved complete remission, 45 after one induction course and 16 of them underwent autologous bone marrow transplantation a median of 11 months later. As of December 1997 (median follow-up 112 months, range 50-135 months), 16 patients were still in complete remission (10 after autologous bone marrow transplantation, 6 after high-dose Ara-C) and 29 had relapsed (median time to relapse 14 months, range 2-75 months). Four patients died in complete remission. The median disease-free survival was 25 months; the 50-months and 10-year disease-free survival were 41% and 35% respectively. No significant differences were observed between the autologous bone marrow transplantation and high-dose Ara-C treated patients whose complete remission had lasted more than 11 months. The median disease-free survival in the autografted patients had not been reached after 120 months (the 50-month and 10-year disease-free survival chances were both 67%). Age was the only predictive variable for leukemic relapse. These long-term results confirm the antileukemic efficacy of an idarubicin-containing protocol, which led to high complete remission rates and favorably influenced disease-free survival. Furthermore, the efficacy of late intensification treatment with either autologous bone marrow transplantation or high-dose Ara-C is underscored. The disease-free survival chances after autologous bone marrow transplantation are comparable with those published for allogeneic bone marrow transplantation; however, disease-free survival of the patients receiving a high-dose Ara-C intensification regimen is not significantly worse than that seen after autologous bone marrow transplantation.

Catalog

Books, media, physical & digital resources
See catalog results